Kathleen M. Cain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathleen M. Cain has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Perdita Elizabeth Barran
University of Manchester
3 shared publications - Andrew Pitt
University of Manchester
2 shared publications - Charles Eldrid
University of Manchester
2 shared publications - Jean-Marc Schwartz
University of Manchester
2 shared publications - Reynard Spiess
University of Manchester
2 shared publications - Akshada Gajbhiye
Laboratory for Biological Mass Spectrometry, Newcastle University, Newcastle upon Tyne, UK
1 shared publication
Latest Publications
- Open Access
- 4 June 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (7) , 101011
From Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing
- 4 June 2025
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 24 (7) , 101011
Open AccessFrom Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing
- Open Access
- 19 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
From Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing
Chinese hamster ovary (CHO) cells are the industrial workhorse for manufacturing biopharmaceuticals, including monoclonal antibodies. CHO cell line development requires a more data-driven approach for the accelerated identification of hyper-productive cell lines. Traditional methods, which rely on time-consuming hierarchical screening, often fail to elucidate the underlying cellular mechanisms driving optimal bioreactor performance. Big data analytics, coupled with advancements in ‘omics’ technologies, are revolutionizing the study of industrial cell lines. However, translating this knowledge into practical methods widely utilized in industrial biomanufacturing remains a significant challenge. This study leverages discovery proteomics to characterize dynamic changes within the CHO cell proteome during a 14 day fed-batch bioreactor cultivation. Utilizing a global untargeted proteomics workflow, we identify 3358 proteins, using a ZenoTOF 7600 and a Cyclic IMS QToF. By mapping relative abundances to key cellular processes, eight protein targets were selected as potential biomarkers. To bridge the gap between discovery and industrial applications, we translated these findings into a rapid 15 minute targeted triple quadrupole (MRM) assay. This approach demonstrates the potential of repurposing discovery proteomics for targeted biomarker identification in biotherapeutic production. By monitoring these biomarkers we can potentially streamline the screening of biomanufacturing cell lines and culture conditions, ultimately accelerating biotherapeutic development.
- 19 November 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessFrom Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing
Chinese hamster ovary (CHO) cells are the industrial workhorse for manufacturing biopharmaceuticals, including monoclonal antibodies. CHO cell line development requires a more data-driven approach for the accelerated identification of hyper-productive cell lines. Traditional methods, which rely on time-consuming hierarchical screening, often fail to elucidate the underlying cellular mechanisms driving optimal bioreactor performance. Big data analytics, coupled with advancements in ‘omics’ technologies, are revolutionizing the study of industrial cell lines. However, translating this knowledge into practical methods widely utilized in industrial biomanufacturing remains a significant challenge. This study leverages discovery proteomics to characterize dynamic changes within the CHO cell proteome during a 14 day fed-batch bioreactor cultivation. Utilizing a global untargeted proteomics workflow, we identify 3358 proteins, using a ZenoTOF 7600 and a Cyclic IMS QToF. By mapping relative abundances to key cellular processes, eight protein targets were selected as potential biomarkers. To bridge the gap between discovery and industrial applications, we translated these findings into a rapid 15 minute targeted triple quadrupole (MRM) assay. This approach demonstrates the potential of repurposing discovery proteomics for targeted biomarker identification in biotherapeutic production. By monitoring these biomarkers we can potentially streamline the screening of biomanufacturing cell lines and culture conditions, ultimately accelerating biotherapeutic development.
- Open Access
- 2 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Development and translation of a method of clinical utility for LC-MS/MS analysis to detect SARS-CoV-2 antigens from ONP swabs and saliva
During the COVID-19 pandemic, development of diagnostic tests was vital to chart the course and to reduce the impact of the infection. Continued testing and surveillance of vaccine escape will continue for years to come which presents an opportunity to integrate such testing into clinical biochemistry laboratories that form part of integrated healthcare testing. Here we describe a protocol for a targeted mass spectrometry based proteomic assay (COVIDCAP) developed to detect SARS-CoV-2 peptides from oro-nasopharyngeal swabs (ONP) and saliva. This uses novel SISCAPA antibodies bound to magnetic beads and subsequent analysis of captured and purified SARS-CoV-2 nucleocapsid (NCAP) peptides. The method involves immediate deactivation of the sample using an ethanolic solution. This simultaneously inactivates the virus and denatures viral proteins at sampling in contrast to the approach for RT-PCR testing, with benefits for the assay as well as for downstream processing. A plate-based preparation of the samples involving acetone precipitation followed by a short tryptic digestion and subsequent immunocapture allows LC-MS detection and quantification of peptides from the NCAP protein, in a 3-minute inject-to-inject assay with an LOD of 20 attomoles from starting sample. For 576 ONP swab samples taken as exemplars here, the sensitivity and specificity of this analysis is shown to be 97.0% and 96.6% respectively.
- 2 September 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDevelopment and translation of a method of clinical utility for LC-MS/MS analysis to detect SARS-CoV-2 antigens from ONP swabs and saliva
During the COVID-19 pandemic, development of diagnostic tests was vital to chart the course and to reduce the impact of the infection. Continued testing and surveillance of vaccine escape will continue for years to come which presents an opportunity to integrate such testing into clinical biochemistry laboratories that form part of integrated healthcare testing. Here we describe a protocol for a targeted mass spectrometry based proteomic assay (COVIDCAP) developed to detect SARS-CoV-2 peptides from oro-nasopharyngeal swabs (ONP) and saliva. This uses novel SISCAPA antibodies bound to magnetic beads and subsequent analysis of captured and purified SARS-CoV-2 nucleocapsid (NCAP) peptides. The method involves immediate deactivation of the sample using an ethanolic solution. This simultaneously inactivates the virus and denatures viral proteins at sampling in contrast to the approach for RT-PCR testing, with benefits for the assay as well as for downstream processing. A plate-based preparation of the samples involving acetone precipitation followed by a short tryptic digestion and subsequent immunocapture allows LC-MS detection and quantification of peptides from the NCAP protein, in a 3-minute inject-to-inject assay with an LOD of 20 attomoles from starting sample. For 576 ONP swab samples taken as exemplars here, the sensitivity and specificity of this analysis is shown to be 97.0% and 96.6% respectively.